Pacific Biosciences of California (NASDAQ: PACB) insider transactions
In the twelve months to 10 November 2026, executives and directors of Pacific Biosciences of California reported 12 open-market sales of 1,506,622 shares ($3.4m) and 0 open-market purchases, by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 6 October 2026 | Gibson James R II | See Remarks | Option exercise, 10b5-1 plan | +500,000 | $1.18 | 1,745,663 | Form 4 |
| 6 October 2026 | Gibson James R II | See Remarks | Open-market sale, 10b5-1 plan | −661,815 | $3.11 | 1,083,848 | Form 4 |
| 17 August 2026 | Van Oene Mark | See Remarks | Open-market sale | −26,911 | $1.13 | 2,705,853 | Form 4 |
| 10 August 2026 | Van Oene Mark | See Remarks | Grant or award | +489,130 | — | 2,732,764 | Form 4 |
| 8 April 2026 | Gibson Christopher | Director | Grant or award | +57,473 | — | 111,386 | Form 4 |
| 1 April 2026 | Gibson James R II | See Remarks | Open-market sale | −88,185 | $1.37 | 1,245,663 | Form 4 |
| 3 March 2026 | Gibson Christopher | Director | Grant or award | +53,913 | — | 53,913 | Form 4 |
| 3 March 2026 | Farmer Michele | See Remarks | Open-market sale | −2,979 | $1.51 | 305,948 | Form 4 |
| 3 March 2026 | Van Oene Mark | See Remarks | Open-market sale | −6,504 | $1.51 | 2,243,634 | Form 4 |
| 3 March 2026 | Henry Christian O | See Remarks | Open-market sale | −12,497 | $1.51 | 3,581,813 | Form 4 |
| 27 February 2026 | Henry Christian O | See Remarks | Grant or award | +920,810 | — | 3,594,310 | Form 4 |
| 27 February 2026 | Van Oene Mark | See Remarks | Grant or award | +500,000 | — | 2,242,638 | Form 4 |
| 27 February 2026 | Gibson James R II | See Remarks | Grant or award | +333,848 | — | 1,333,848 | Form 4 |
| 27 February 2026 | Farmer Michele | See Remarks | Grant or award | +89,835 | — | 308,927 | Form 4 |
| 18 February 2026 | Farmer Michele | See Remarks | Open-market sale | −14,952 | $1.63 | 219,092 | Form 4 |
| 18 February 2026 | Henry Christian O | See Remarks | Open-market sale | −140,874 | $1.63 | 2,673,500 | Form 4 |
| 18 February 2026 | Van Oene Mark | See Remarks | Open-market sale | −55,107 | $1.63 | 1,742,638 | Form 4 |
| 17 February 2026 | Farmer Michele | See Remarks | Open-market sale | −35,215 | $1.58 | 234,044 | Form 4 |
| 17 February 2026 | Henry Christian O | See Remarks | Open-market sale | −331,793 | $1.58 | 2,814,374 | Form 4 |
| 17 February 2026 | Van Oene Mark | See Remarks | Open-market sale | −129,790 | $1.58 | 1,797,745 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Pacific Biosciences of California page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.